Pharmaceutical Contract Manufacturing (3rd Edition), 2021-2030 Distribution by [A] business segment (API and FDF), [B] type of API (branded and generic), [C] type of FDF (oral solids, parenteral and others), [D] type of packaging form (blisters, bottles,

Pharmaceutical Contract Manufacturing (3rd Edition), 2021-2030 Distribution by [A] business segment (API and FDF), [B] type of API (branded and generic), [C] type of FDF (oral solids, parenteral and others), [D] type of packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] end-users (large pharmaceutical companies, mid-sized pharmaceutical companies and small pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle-East and North Africa): Industry Trends and Global Forecasts

At present, the pharmaceutical industry is dominated by the presence of small molecule products, which represent close to 80% of the overall pipeline. Even though biologics have shown significant promise in the treatment of a wide range of disorders, in recent years, approval of novel small molecules has been on the rise. In fact, in 2020, over 50 small molecule drugs were approved by the US FDA, while around 8,000 such candidates are being evaluated across different stages of development. It is worth mentioning that the pipeline features increasingly complex candidates, which require specialized facilities, advanced equipment and operational expertise. As setting-up / acquiring manufacturing capabilities is both time and cost intensive process, it is extremely challenging for pharmaceutical companies to perform development and manufacturing operations independently. The aforementioned constraints, coupled to the rising demand for safer and effective drugs (currently driven by the COVID-19 pandemic), have prompted players to outsource a significant portion of their business segments to contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs).

The current landscape of pharmaceutical contract service providers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. The inherent expertise of CMOs and CDMOs is believed to be capable of enabling reduction in the time-to-market a product, significant cost-benefits, as well as access to larger production capacities and novel technologies. It is worth mentioning that there has been substantial merger and acquisition activity in the pharmaceutical contract manufacturing market in the past few years, as players strive to become one stop shops, in order to cater to the diverse needs of pharmaceutical developers (ranging from early-stage development to commercial production). Considering the ongoing innovation in production technologies, evolving pipeline of small molecule products and the increasing demand for such drug candidates, we believe that the pharmaceutical contract manufacturing market is likely to witness positive growth in the coming years.

SCOPE OF THE REPORT
The “Pharmaceutical Contract Manufacturing Market (3rd Edition) Distribution by [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa.: Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing industry. Amongst the other elements, the report features:
 A detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).
 A detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm.
 A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).
 An estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific).
 Informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions.
 A detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.
 A detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation.
 A detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies.
 Elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.
 A case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.
 A qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
 A detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market based on several parameters, such as growth of the overall pharmaceutical market, cost of goods sold, direct manufacturing costs. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the opportunity across [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. In order to account for future uncertainties and add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
 Scott Goldstein (Ex - Director, Business Development, Ajinomoto Bio-Pharma Services)
 Thomas Früh (Ex - CEO, Bachem)
 Bhaskar Venepalli (President and CEO, CiVentiChem)
 Roberto Margarita (Director, Business Development, CordenPharma)
 Allison Vavala (Director, Commercial Development, Helsinn Group)
 Kevin Daley (Director, Pharmaceuticals Marketing, Novasep)
 Piyush Desai (Director, Operations, Sovereign Pharma)
 Ilan Avni (Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The research, analysis and insights presented in this report are backed by a deep understanding of insights gathered from both secondary and primary sources. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
 Who are the key players engaged in offering contract manufacturing services for small molecules?
 What are the key value drivers of the merger and acquisition activity observed within the pharmaceutical contract manufacturing industry?
 What are the different expansion initiatives undertaken by pharmaceutical contract manufacturers in the recent past?
 Which regions represent the current key contract manufacturing hubs for small molecules?
 What is the current, installed capacity for contract manufacturing of small molecules?
 What is the current, global demand for small molecules? How is the demand for such candidates likely to evolve in the foreseen future?
 What percentage of the pharmaceutical manufacturing operations are presently outsourced?
 What factors should be taken into consideration while deciding whether the manufacturing operations for small molecules should be kept in-house or outsourced?
 How is the current and future opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the pharmaceutical contract manufacturing market in the mid-long term.

Chapter 3 provides a general introduction to various type of manufacturers engaged in the pharmaceutical market. It further includes a brief overview of the concept of contract manufacturing, featuring a discussion on the evolution of contract services in this industry. Additionally, it highlights details related to the need for outsourcing in this domain. Further, the chapter includes a brief overview of contract manufacturing models that have been adopted in the pharmaceutical industry and an exhaustive list of services offered by CMOs; the chapter concludes with a discussion on the challenges associated with the outsourcing of pharmaceutical manufacturing operations.

Chapter 4 features a detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies

Chapter 5 provides a detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).

Chapter 6 presents a detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.

Chapter 7 features elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.

Chapter 8 presents a qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.

Chapter 9 presents a detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm.

Chapter 10 features A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).

Chapter 11 features an estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 12 provides informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions, based on relevant parameters, such as number of patient population, dosage and dose frequency.

Chapter 13 represents a detailed market forecast, highlighting the future potential of the pharmaceutical contract manufacturing market, till 2030. Additionally it features the likely distribution of the opportunity across different [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (large pharmaceutical companies, mid-sized pharmaceutical companies and small pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa.

Chapter 14 presents a detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation.

Chapter 15 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.

Chapter 16 is a case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 18 is a collection of executive insight(s) of the discussion(s) that were held with key stakeholder(s) in this market. We have presented details of interviews held with Scott Goldstein (Ex - Director, Business Development, Ajinomoto Bio-Pharma Services), Thomas Früh (Ex - CEO, Bachem), Bhaskar Venepalli (President and CEO, CiVentiChem), Roberto Margarita (Director, Business Development, CordenPharma), Allison Vavala (Director, Commercial Development, Helsinn Group), Kevin Daley (Director, Pharmaceuticals Marketing, Novasep), Piyush Desai (Director, Operations, Sovereign Pharma), Ilan Avni (Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which provides the list of companies and organizations included in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been included in the report:

1. A. S. Joshi & Company
2. Aarti Industries
3. AbbVie
4. Abiogen Pharma
5. Accra Pac
6. ACIC Pharmaceuticals
7. Acino
8. Acme Group
9. Acorda Therapeutics
10. ACS Dobfar
11. Actiza Pharmaceutical
12. Adare Pharmaceuticals
13. Admac Formulations
14. Advent International
15. Aenova
16. Afton Scientific
17. AGIC Capital
18. Agno Pharma
19. Aiomedic Pharmaceuticals
20. AiPing Pharmaceutical
21. Ajinomoto Bio-Pharma Services
22. Akorn
23. Akrikhin
24. Akums Drugs & Pharmaceuticals
25. Albatross Pharmaceuticals
26. Albemarle
27. AlbyPharma
28. Alcami
29. Alembic Pharmaceuticals
30. Alkem Laboratories
31. Alkermes
32. Allchem Laboratories
33. Almac
34. Almelo
35. Alps Pharmaceutical
36. Altasciences
37. Althea Pharma
38. Alvogen
39. Amanta Healthcare
40. AmbioPharm
41. American Regent
42. Ami Lifesciences
43. Amman Pharmaceutical Industries
44. Amneal Pharmaceuticals
45. Amoli Organics
46. AMPAC Fine Chemicals
47. AMRI
48. Angelini Pharma
49. Anhui Biochem United Pharmaceutical
50. ANI Pharmaceuticals
51. Ankur Drugs and Pharma
52. Anqiu Lu'an Pharmaceutical
53. Anugraha Chemicals
54. ANVI Pharma
55. API Co. Ltd
56. API Pharma Tech
57. Apicore
58. Apiscent Laboratories (acquired by Kingchem Life Sciences)
59. APL Pharma Specials
60. Appco Pharma
61. Aptuit
62. Arbro Pharmaceuticals
63. Arch Pharmalabs
64. Arcinova
65. Ardena
66. Arevipharma
67. Argonaut
68. Aristo Pharma
69. Arvincare
70. Aspen
71. Aspen Pharmacare
72. Aster Pharma
73. Asymchem
74. Atra Pharmaceuticals
75. Aurigene Pharmaceutical Services
76. Aurobindo Pharma
77. Austar Pharma
78. Avara Pharmaceutical Services
79. Avra Laboratories
80. AVVA Pharmaceuticals
81. Axa Parenterals
82. Baccinex
83. Bachem
84. Bal Pharma
85. Bankyo Pharmaceutical
86. Batterjee Pharma
87. Bausch Health
88. Baxter
89. Baxter BioPharma Solutions
90. BCN Peptides
91. BDR Pharmaceuticals
92. Belco Pharma
93. Bellwyck Pharma Services (acquired by PCI Pharma Services)
94. Beltapharm
95. Bennet Pharmaceuticals
96. BePharBel
97. Beximco Pharmaceuticals
98. BINEX
99. Biological E
100. Biophore
101. Bioserv
102. Biosint
103. Bio-Synthesis
104. BioVectra
105. Biozoc
106. Bluepharma
107. Bonarum Pharma
108. Bora Pharmaceuticals
109. Brassica Pharma
110. Bridgepoint
111. Bristol Laboratories
112. Broad Pharmaceutical
113. Bushu Pharma
114. Cadila Pharmaceuticals
115. Calyx Chemicals & Pharmaceuticals
116. Cambrex
117. Canonpharma
118. Caplin Point Laboratories
119. Capsugel
120. CARBOGEN AMCIS
121. Carlyle Group
122. Cascade Chemistry
123. Catalent
124. Cayman Chemical
125. Cenexi
126. Centaur Pharmaceuticals
127. Century Pharmaceuticals
128. Cerbios-Pharma
129. Chartwell Pharmaceuticals
130. ChemCon
131. ChemConnection
132. Chemigran
133. ChemPacific
134. Chiral Biosciences
135. Chirogate International
136. Chongqing Huapont Pharmaceutical
137. Chromo Laboratories
138. Chunghwa Chemical Synthesis & Biotech
139. Ciron Drugs
140. CiVentiChem
141. CJ HealthCare
142. Claris Injectables (acquired by Baxter)
143. Clearsynth
144. CMIC Group
145. Coating Place
146. Concord Drugs
147. Confab Laboratories
148. Consort Medical
149. Contract Coating
150. Contract Pharmacal
151. Copperhead Chemical Company
152. CordenPharma
153. CoreRx
154. CPC Scientific
155. Contract Pharmaceuticals Limited (CPL)
156. Crenza Pharmaceuticals
157. Cris Pharma
158. Crown Laboratories
159. CTX Lifesciences
160. Daiichi Sankyo
161. Daito Pharmaceutical
162. Dalton Pharma Services
163. DBK Pharmaceutical
164. Dearborn Partners
165. Dechra Pharmaceuticals
166. Delmar Chemicals
167. Delpharm
168. Delta Laboratories
169. Dermopartners
170. DEVA
171. Dhanuka Labortories
172. Dhruv Life Sciences
173. Dipharma
174. Dishman Biotech (acquired by CARBOGEN AMCIS)
175. DIVERCHIM
176. Divi's Laboratories
177. DM Pharma Marketing
178. Dottikon Exclusive Synthesis
179. Douglas Pharmaceuticals
180. DPT Laboratories
181. Dr. Pradeep Reddy's Laboratories
182. Dupen Laboratories
183. Dwarkesh Pharmaceuticals
184. EirGen Pharma
185. E.L. Laboratories
186. Elfin
187. Elite Pharmaceuticals
188. Embio
189. Emcure Pharmaceuticals
190. Emergent BioSolutions
191. Eminent Healthcare
192. Enaltec
193. Entema Laboratories
194. Entod Pharmaceuticals
195. Epic Pharma
196. Ercros
197. Eriochem
198. Erregierre
199. Esteve
200. Ethypharm
201. Eurofins
202. Euro-Med Laboratories
203. EVER Pharma
204. Evonik Industries
205. Evotec
206. Exela Pharma Sciences
207. FAMAR
208. Fareva
209. Farmak
210. Farmasierra
211. Farmhispania Group
212. Farmigea
213. Fermion
214. Ferndale laboratories
215. FineTech Pharmaceuticals
216. Flamingo Pharmaceuticals
217. Flamma
218. Fleming Laboratories
219. Fresenius Kabi
220. FTF Pharma
221. Fuji Chemical
222. Fuji Pharma
223. Fujifilm RI Pharma
224. Fujimoto Chemicals
225. Future Pak
226. Galentic Pharma
227. G.D Pharmaceuticals
228. Gebro Pharma
229. Gedeon Richter
230. General Atlantic
231. Getz Pharma
232. GHO Capital
233. Gland Pharma
234. Glatt
235. GlaxoSmithKline
236. Glenmark Pharmaceuticals
237. Globela Pharma
238. Glochem Industries
239. GP Pharm
240. Grand River Aseptic Manufacturing
241. Granules India
242. Grindeks
243. Groupe PARIMA
244. Grünenthal
245. Guardian Drug Company
246. GVK BIO
247. Halo Pharma
248. Handok
249. Hanford Pharmaceuticals
250. Hangzhou Hysen Pharma
251. Hanuchem Laboratories
252. HBM Pharma
253. Health Biotech
254. Healthy Life Pharma
255. Helios Pharmaceuticals
256. Helsinn Group
257. Hetero Drugs
258. H.I.G Capital
259. Hikal
260. Hovione
261. HP Toride Pharma
262. Hritik Chemicals
263. Hubei Biocause Pharmaceutical
264. Huvepharma
265. ICROM
266. IDT Australia
267. Impopharma (acquired by Rubicon Research)
268. Indena
269. Indoco Remedies
270. Ind-Swift Laboratories
271. Ingenus Pharmaceuticals
272. Innova Captab
273. Intas Pharmaceuticals
274. Interquim
275. Ipca Laboratories
276. i-Pharmaceuticals
277. Isochem (acquired by PMC Group)
278. Iwaki Seiyaku Sakura Factory
279. JB Chemicals and Pharmaceutical
280. Jay Chemicals
281. Jadran Galenski Laboratory (JGL)
282. J-Star Research
283. Jubilant Biosys
284. Kalexsyn
285. Kamat Pharmatech
286. Katsura Chemical
287. Kekule Pharma
288. Kemwell Biopharma
289. Kilitch Drugs
290. Kingchem Life Sciences
291. Kohlberg & Company
292. Kokando
293. Kolmar
294. Kongo Chemical
295. Korten
296. KP Pharmaceutical Technology
297. Krebs Biochemicals
298. Kryptochem Medicament
299. Kyoto Pharmaceutical
300. Kyowa Pharma Chemical
301. Laboratorios Farmacéuticos ROVI
302. Laboratorios Inibsa
303. Salvat
304. Lameplast
305. Lamplast
306. Laurus Labs
307. Lebsa
308. Lenus Lifecare
309. LGM Pharma
310. Lifekyor Pharmaceuticals
311. Lloyd Laboratories
312. LOBA Feinchemie
313. Logos Pharma
314. Lomapharm
315. Lonza
316. Lotus Pharma
317. LSNE
318. Lubrizol Life Science
319. Luitpold Pharmaceuticals
320. Lyne Laboratories
321. M2i
322. Macter
323. Madras Pharmaceuticals
324. Maiva Pharma
325. Makcur Laboratories
326. Malladi Drugs & Pharmaceuticals
327. Matreya
328. Maxtar Bio Genics
329. McGuff Pharmaceuticals
330. Medical Product Laboratories
331. Medichem
332. Medilux Laboratories
333. Mediwin Pharmaceuticals
334. MedPharm
335. Mehta API
336. Menadiona
337. Symeres
338. Metrics Contract Services
339. Metrochem API
340. Micro Labs
341. Micro-Sphere
342. Mikart
343. MINAKEM
344. Mipharm
345. MSN Laboratories
346. Multi Packaging Solutions
347. Multi-Pack Solutions
348. Murty Pharmaceuticals
349. Nagase Medicals
350. Nakoda Chemicals
351. Nanjing Pharmatechs
352. Natco Pharma
353. Nautic Partners
354. Nectar Lifesciences
355. Neiss Labs
356. Nephron Pharmaceutuicals
357. NerPharma
358. Neuland Laboratories
359. Nexgen Pharma (acquired by LGM Pharma)
360. Nextar Chempharma Solutions
361. NextPharma
362. Nippon Rika Technologies
363. Nipro Pharma
364. Nitto Avecia
365. Nivon Specialties
366. Norac Pharma
367. Norchim
368. Novacap
369. NovaQuest
370. Novartis
371. Novasep
372. Novo Holdings
373. Nutragen Pharma
374. Nutraplus India
375. Nvron Life Science
376. Oakwood Labs
377. Oasis Laboratories
378. Oceanic Pharmachem
379. Olainfarm
380. Olic (Thailand)
381. Olon
382. Oman Pharmaceutical Products
383. Oncotec Pharma Produktion
384. Orbis Biosciences
385. Orchid Pharma
386. Orient Pharma
387. Orion
388. Orofino Pharmaceuticals
389. Otsuka Pharmaceutical
390. Panacea Biotec
391. PannonPharma
392. Parabolic Drugs
393. Patheon
394. PCI Pharma Services
395. Pegasus Farmaco
396. Penmix
397. Perrigo
398. Pfizer
399. Pfizer CentreOne
400. Pharma Stulln
401. PharmAgra Labs
402. Pharma-Q
403. Pharmascience
404. Pharmasol
405. PharmaSynth
406. PharmaZell
407. Pharmed Healthcare
408. Pharmer
409. Phekolong Pharmaceuticals (Laurus Labs)
410. Phytex Australia
411. Phyton Biotech
412. Pidolma Healthcare
413. Pharmaceutical Institute of India (Pii)
414. Pillar5 Pharma
415. PIQ-Pharma
416. Piramal Pharma
417. PiSA Farmaceutica
418. Pisgah Labs (acquired by Ipca Laboratories)
419. i Group
420. PMRS
421. Polfa Tarchomin
422. Polpharma
423. Poly Pharmaceuticals
424. PolyPeptide
425. Porton Fine Chemicals
426. Permira
427. PrimaPharma
428. Prisha Healthcare
429. Priyans Drugs
430. Procaps
431. Procos
432. Pyramid Pharma
433. Qualiphar-Gifrer
434. Quality Chemical Laboratories
435. Quay Pharmaceuticals
436. Que Pharma
437. Quotient Sciences
438. Radico Remedies
439. Rafarm
440. Raybow PharmScience
441. Recipharm
442. Redwing Pharma
443. Regis Technologies
444. Remington Pharmaceuticals
445. Olon Ricerca Biosciences
446. Ritedose
447. Rivopharm
448. RL Fine Chem
449. Robinson Brothers
450. Rommelag
451. Rompharm
452. Rottendorf Pharma
453. Rubicon Research
454. Rusan Pharma
455. S M Pharmaceuticals
456. Sai Life Sciences
457. Sandoz
458. Sanico
459. Sannova Biotech
460. Sanochemia Pharmazeutika
461. Santen Pharmaceutical
462. Sanwa Kagaku Kenkyusho
463. Sarvodaya Drugs and Pharmaceuticals
464. Sarvotham Care
465. Sato Yakuhin Kogyo
466. SAVA Healthcare
467. Savior Lifetec
468. SCI Pharmatech
469. ScinoPharm
470. Seacross Pharmaceuticals
471. Seikagaku
472. Sekisui Medical
473. Selvok Pharmaceutical
474. Sentiss Pharma
475. Seqens
476. Shandong Xinhua Pharmaceutical
477. Sharon Bio-Medicine
478. Shilpa Medicare
479. Siegfried
480. Sigmapharma Laboratories
481. Sinopharm
482. Sirio Pharma
483. SK biotek
484. SK Holdings
485. Smruthi Organics
486. SMS Pharmaceuticals
487. Societa Italiana Medicinali Scandicci
488. Softgel Healthcare
489. Solara Active Pharma Sciences
490. Solopharm
491. Sovereign Pharmaceuticals
492. SPC Lifesciences
493. Square Pharmaceuticals
494. Stason Pharmaceutical
495. Stelis Biopharma
496. Stericon Pharma
497. Sterling Pharma Solutions
498. Sterling Pharmaceuticals
499. Sunrise Pharmaceutical
500. Sunways
501. Supriya LifeScience
502. Suven Life Sciences
503. Swiss Pharma
504. Symed Labs
505. Synbias Pharma
506. Syncom Healthcare
507. Syngene
508. Synthokem Labs
509. Sypharma
510. Syntegon
511. Tahira Industries
512. Tai Heng Industry
513. Taiyo Pharma Tech
514. Tatchempharmpreparaty
515. Tedor Pharma
516. Teika Pharmaceutical
517. Tekni-Plex
518. Teligent
519. Teva Pharmaceuticals
520. Theon Pharmaceuticals
521. Thermo Fisher Scientific
522. Titan Pharmaceuticals
523. Toa Pharmaceutical
524. Tolmar
525. Torrent Pharmaceuticals
526. FUJIFILM Toyama Chemical
527. TriPharm Services (acquired by Alcami)
528. Trugen Pharma
529. Tyger Scientific
530. UBE Industries
531. Ultratech India
532. Unibiotech Formulations
533. Unichem Laboratories
534. Unimark Remedies
535. Unison Chemical Works
536. UPM Pharmaceutical
537. Uquifa
538. Ursapharm Arzneimittel
539. US Pharma Lab
540. USV
541. Vanamali Organics (acquired by Wavelength Pharmaceuticals)
542. Vetter Pharma
543. Vinkem Labs
544. Vital Healthcare
545. VUAB Pharma (SAFICHEM)
546. Wanbury
547. Wavelength Pharmaceutical
548. WCCT Global
549. WDPrx- Woodfield Pharmaceutical
550. WellSpring Pharmaceuticals
551. West Pharmaceutical Services
552. WestRock
553. Wilmington PharmaTech
554. Windlas Healthcare
555. Wintac
556. Wisdom Pharmaceuticals
557. Wockhardt
558. WuXi AppTec
559. Xellia Pharmaceuticals
560. Xi'an Lijun Pharmaceutical
561. Xttrium Laboratories
562. YaoPharma
563. Yash Pharma Laboratories
564. Yegna Manojavam Drugs and Chemicals (acquired by PMC Group)
565. Yuhan
566. Yung Zip Chemical
567. Zach Systems (Zambon)
568. ZCL Chemicals (acquired by Advent International)
569. Zenith Healthcare
570. Zenlabs
571. ZheJiang Apeloa JiaYuan Pharmaceutical
572. Zhejiang Changming Pharmaceutical
573. Zhejiang Cheng Yi Pharmaceutical
574. Zhejiang Excel Pharmaceutical
575. Zhejiang Hisun Pharmaceutical
576. Zhejiang Huahai Pharmaceutical

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.